A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma

Exclusion Criteria

• •Patients with known allergic reactions to any component or excipient of piteutinib;
• •Patients concurrently participating in other clinical studies;
• •A history of clinically significant, uncontrolled cardiac,
• •Cardiovascular disease, or myocardial infarction within 6 months prior to planned initiation of piteutinib therapy;
• •Uncontrolled systemic bacterial, viral, fungal, or parasitic infections; current use of potent CYP3A4 inhibitors or inducers and/or potent P-gp inhibitors;
• •Positive human immunodeficiency virus (HIV) testing;
• •Active hepatitis B or C: 1) Patients with positive hepatitis B virus (HBV) DNA testing and controlled disease status may be enrolled with investigator approval. For HBV DNA-positive patients, concurrent antiviral therapy is required. 2) Patients with prior hepatitis C virus (HCV) infection history who have completed antiviral therapy with viral loads below the quantitative limit may be enrolled;
• •Based on the investigator's assessment, participants may be unable to complete all study protocol requirements, including follow-up visits, and/or adhere to all study procedures;
• •A history of other clinically significant diseases or comorbidities; and any safety risks or potential interference with study completion as evaluated by investigators.